{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:24:44Z","timestamp":1751430284804,"version":"3.41.0"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Laryngorhinootologie"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Invasive Pilzerkrankungen sind schwer zu behandeln und stellen eine erhebliche Bedrohung f\u00fcr immungeschw\u00e4chte Menschen dar. Die derzeitigen antimykotischen Wirkstoffe sto\u00dfen an ihre Grenzen, einschlie\u00dflich zunehmender Resistenzen gegen Antimykotika und unerw\u00fcnschter Wirkungen. Diese \u00dcbersicht soll einen umfassenden \u00dcberblick \u00fcber neue Behandlungsstrategien geben.<\/jats:p>","DOI":"10.1055\/a-2341-0404","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T23:44:41Z","timestamp":1722296681000},"page":"418-425","source":"Crossref","is-referenced-by-count":0,"title":["Invasive Mykosen \u2013 Innovative Therapien"],"prefix":"10.1055","volume":"104","author":[{"given":"Sibylle C.","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Klinik I f\u00fcr Innere Medizin, Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[{"name":"Klinik I f\u00fcr Innere Medizin, Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvin","family":"Mammadova","sequence":"additional","affiliation":[{"name":"Klinik I f\u00fcr Innere Medizin, Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum K\u00f6ln (A\u00f6R), K\u00f6ln"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannik","family":"Stemler","sequence":"additional","affiliation":[{"name":"Klinik I f\u00fcr Innere Medizin, Universit\u00e4tsklinikum K\u00f6ln, K\u00f6ln, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"TF Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","article-title":"COVID-19-associated fungal infections","volume":"7","author":"M Hoenigl","year":"2022","journal-title":"Nat Microbiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/cid\/ciac882","article-title":"The Geographic Distribution of Dimorphic Mycoses in the United States for the Modern Era","volume":"76","author":"PB Mazi","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"S 07","key":"ref4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"OA Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1093\/jac\/dkx133","article-title":"Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia","volume":"72","author":"OA Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3109\/1040841X.2014.910749","article-title":"Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi","volume":"42","author":"P Koehler","year":"2016","journal-title":"Crit Rev Microbiol"},{"issue":"S 02","key":"ref7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/milmed\/usy079","article-title":"Treatment of Suspected Invasive Fungal Infection in War Wounds","volume":"183","author":"CJ Rodriguez","year":"2018","journal-title":"Mil Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"J Stemler","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/jof5030067","article-title":"Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens","volume":"5","author":"DZP Friedman","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"FM Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"M Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/13543784.2022.2086120","article-title":"Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action","volume":"31","author":"M Hoenigl","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"GR Thompson GR 3rd","year":"2023","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e0141922","DOI":"10.1128\/aac.01419-22","article-title":"Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial","volume":"67","author":"JA Vazquez","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis","volume":"17","author":"D Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13054-016-1182-z","article-title":"T cells from patients with Candida sepsis display a suppressive immunophenotype","volume":"20","author":"A Spec","year":"2016","journal-title":"Crit Care"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"ME Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3390\/ijms18112413","article-title":"Targeting Immune Cell Checkpoints during Sepsis","volume":"18","author":"NK Patil","year":"2017","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/cc13176","article-title":"Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis","volume":"18","author":"K Chang","year":"2014","journal-title":"Crit Care"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.1097\/HS9.0000000000000530","article-title":"Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection","volume":"5","author":"JC Banck","year":"2021","journal-title":"Hemasphere"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2022.06.035","article-title":"Nivolumab induces long-term remission in a patient with fusariosis","volume":"173","author":"E Khatamzas","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mmcr.2022.06.003","article-title":"Nivolumab and interferon-\u03b3 rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock","volume":"37","author":"AC Lukaszewicz","year":"2022","journal-title":"Med Mycol Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"900522","DOI":"10.3389\/fimmu.2022.900522","article-title":"Case Report: Immune Checkpoint Blockade Plus Interferon-\u0393 Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis","volume":"13","author":"A Serris","year":"2022","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/myc.12919","article-title":"Mould-reactive T cells for the diagnosis of invasive mould infection-A prospective study","volume":"62","author":"A Steinbach","year":"2019","journal-title":"Mycoses"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3389\/fimmu.2017.01939","article-title":"Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells","volume":"8","author":"PR Kumaresan","year":"2018","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1044946","DOI":"10.3389\/fimmu.2022.1044946","article-title":"Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges","volume":"13","author":"BLZ Oh","year":"2022","journal-title":"Front Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"PR Kumaresan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"eabh1209","DOI":"10.1126\/scitranslmed.abh1209","article-title":"CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models","volume":"14","author":"M Seif","year":"2022","journal-title":"Sci Transl Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"S Prommersberger","year":"2021","journal-title":"Gene Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/S2352-3018(23)00172-8","article-title":"Advancing bnAb combinations for HIV prevention","volume":"10","author":"H Gruell","year":"2023","journal-title":"Lancet HIV"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1038\/s41467-019-08392-x","article-title":"Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis","volume":"9","author":"FM Rudkin","year":"2018","journal-title":"Nat Commun"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.3390\/ijms23105563","article-title":"Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives","volume":"23","author":"X Lian","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/toxins14120874","article-title":"Candidalysin Is the Hemolytic Factor of Candida albicans","volume":"14","author":"S Mogavero","year":"2022","journal-title":"Toxins"},{"issue":"S 01","key":"ref34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/mmy\/myx139","article-title":"Candida vaginitis: virulence, host response and vaccine prospects","volume":"56","author":"F De Bernardis","year":"2018","journal-title":"Med Mycol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/cid\/ciy185","article-title":"A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial","volume":"66","author":"JE Edwards Jr","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41541-021-00294-8","article-title":"Vaccines for human fungal diseases: close but still a long way to go","volume":"6","author":"LVN Oliveira","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e00547","DOI":"10.1128\/mBio.00547-16","article-title":"Induction of Protective Immunity to Cryptococcal Infection in Mice by a Heat-Killed, Chitosan-Deficient Strain of Cryptococcus neoformans","volume":"7","author":"R Upadhya","year":"2016","journal-title":"mBio"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1038\/s41467-019-10486-5","article-title":"Induction of memory-like dendritic cell responses in vivo","volume":"10","author":"CR Hole","year":"2019","journal-title":"Nat Commun"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrmicro.2017.90","article-title":"Aspergillus fumigatus morphology and dynamic host interactions","volume":"15","author":"FL van de Veerdonk","year":"2017","journal-title":"Nat Rev Microbiol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1099\/jmm.0.079681-0","article-title":"Whole glucan particles as a vaccine against murine aspergillosis","volume":"63","author":"KV Clemons","year":"2014","journal-title":"J Med Microbiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e02145","DOI":"10.1128\/mBio.02145-19","article-title":"A Heat-Killed Cryptococcus Mutant Strain Induces Host Protection against Multiple Invasive Mycoses in a Murine Vaccine Model","volume":"10","author":"Y Wang","year":"2019","journal-title":"mBio"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.chom.2015.02.009","article-title":"Calnexin induces expansion of antigen-specific CD4(+) T cells that confer immunity to fungal ascomycetes via conserved epitopes","volume":"17","author":"M W\u00fcthrich","year":"2015","journal-title":"Cell Host Microbe"}],"container-title":["Laryngo-Rhino-Otologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2341-0404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:30:41Z","timestamp":1751409041000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2341-0404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":42,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2341-0404","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0935-8943","1438-8685"],"issn-type":[{"type":"print","value":"0935-8943"},{"type":"electronic","value":"1438-8685"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}